{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:07:08Z","timestamp":1753880828529,"version":"3.41.2"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI093484-01","HHSN272201100028C"],"award-info":[{"award-number":["1R01AI093484-01","HHSN272201100028C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The fluorocycline TP-271 was evaluated in mouse and nonhuman primate (NHP) models of inhalational anthrax. BALB\/c mice were exposed by nose-only aerosol to\n            <jats:named-content content-type=\"genus-species\">Bacillus anthracis<\/jats:named-content>\n            Ames spores at a level of 18 to 88 lethal doses sufficient to kill 50% of exposed individuals (LD\n            <jats:sub>50<\/jats:sub>\n            ). When 21 days of once-daily dosing was initiated at 24 h postchallenge (the postexposure prophylaxis [PEP] study), the rates of survival for the groups treated with TP-271 at 3, 6, 12, and 18 mg\/kg of body weight were 90%, 95%, 95%, and 84%, respectively. When 21 days of dosing was initiated at 48 h postchallenge (the treatment [Tx] study), the rates of survival for the groups treated with TP-271 at 6, 12, and 18 mg\/kg TP-271 were 100%, 91%, and 81%, respectively. No deaths of TP-271-treated mice occurred during the 39-day posttreatment observation period. In the NHP model, cynomolgus macaques received an average dose of 197 LD\n            <jats:sub>50<\/jats:sub>\n            of\n            <jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>\n            Ames spore equivalents using a head-only inhalation exposure chamber, and once-daily treatment of 1 mg\/kg TP-271 lasting for 14 or 21 days was initiated within 3 h of detection of protective antigen (PA) in the blood. No (0\/8) animals in the vehicle control-treated group survived, whereas all 8 infected macaques treated for 21 days and 4 of 6 macaques in the 14-day treatment group survived to the end of the study (56 days postchallenge). All survivors developed toxin-neutralizing and anti-PA IgG antibodies, indicating an immunologic response. On the basis of the results obtained with the mouse and NHP models, TP-271 shows promise as a countermeasure for the treatment of inhalational anthrax.\n          <\/jats:p>","DOI":"10.1128\/aac.01103-17","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T00:40:19Z","timestamp":1502152819000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB\/c Mice and Cynomolgus Macaques"],"prefix":"10.1128","volume":"61","author":[{"given":"Trudy H.","family":"Grossman","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Battelle, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Drabek","sequence":"additional","affiliation":[{"name":"IIT Research Institute, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Gooldy","sequence":"additional","affiliation":[{"name":"CUBRC, Inc., Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry S.","family":"Heine","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa N.","family":"Henning","sequence":"additional","affiliation":[{"name":"Battelle, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winston","family":"Lin","sequence":"additional","affiliation":[{"name":"IIT Research Institute, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph V.","family":"Newman","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Nevarez","sequence":"additional","affiliation":[{"name":"IIT Research Institute, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaylyn","family":"Siefkas-Patterson","sequence":"additional","affiliation":[{"name":"IIT Research Institute, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne K.","family":"Radcliff","sequence":"additional","affiliation":[{"name":"CUBRC, Inc., Buffalo, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce A.","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2236"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1409755"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-4-200602210-00009"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0706.010604"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v3.i1.20"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/hs.2015.0033"},{"key":"e_1_3_2_8_2","first-page":"1","article-title":"Clinical framework and medical countermeasure use during an anthrax mass-casualty incident","volume":"64","author":"Bower WA","year":"2015","unstructured":"Bower WA HendricksKPillaiSGuarnizoJMeaney-DelmanD,Centers for Disease Control and Prevention. 2015. Clinical framework and medical countermeasure use during an anthrax mass-casualty incident. Morb Mortal Wkly Rep64:1\u201322.","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2003.00775.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.6.1902-1907.2002"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh258"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2006.26.1.3"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.130687"},{"key":"e_1_3_2_14_2","volume-title":"Biothrax suspension for intramuscular or subcutaneous injection, prescribing information","author":"Emergent BioDefense Operations Lansing LLC","year":"2015","unstructured":"Emergent BioDefense Operations Lansing LLC. 2015. Biothrax suspension for intramuscular or subcutaneous injection, prescribing information. Emergent BioDefense Operations Lansing LLC,Lansing, MI."},{"key":"e_1_3_2_15_2","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"59","author":"Wright JG","year":"2010","unstructured":"Wright JG QuinnCPShadomySMessonnierN,Centers for Disease Control and Prevention. 2010. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recommend Rep59(RR-6):1\u201330.","journal-title":"MMWR Recommend Rep"},{"key":"e_1_3_2_16_2","volume-title":"Prescribing information for Anthrasil injection for intravenous use","author":"Cangene Corporation","year":"2015","unstructured":"Cangene Corporation. 2015. Prescribing information for Anthrasil injection for intravenous use. Cangene Corporation, Emergent BioSolutions,Winnipeg, MB, Canada."},{"key":"e_1_3_2_17_2","volume-title":"Prescribing information for Raxibacumab injection for intravenous use","author":"GlaxoSmithKline","year":"2016","unstructured":"GlaxoSmithKline. 2016. Prescribing information for Raxibacumab injection for intravenous use. GlaxoSmithKline,Research Triangle Park, NC."},{"key":"e_1_3_2_18_2","volume-title":"Prescribing information for Anthim injection for intravenous use","author":"Elusys Therapeutics, Inc","year":"2016","unstructured":"Elusys Therapeutics, Inc. 2016. Prescribing information for Anthim injection for intravenous use. Elusys Therapeutics, Inc,Pine Brook, NJ."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00004-17"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05724-11"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300985810378112"},{"key":"e_1_3_2_22_2","volume-title":"Product development under the Animal Rule\u2014guidance for industry","author":"FDA","year":"2015","unstructured":"FDA. 2015. Product development under the Animal Rule\u2014guidance for industry. CBER, CDER, FDA, U.S. Department of Health and Human Services."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-06"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00448-17"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/520547"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01109-10"},{"key":"e_1_3_2_27_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother","author":"Grossman TH","year":"2014","unstructured":"Grossman TH LinWSiefkas-PattersonKGooldyMSutcliffeJA. 2014. TP-271, a novel fluorocycline, is efficacious in a post-exposure prophylaxis (PEP) model of aerosolized Yersinia pestis infection in BALB\/c mice, abstr F-1599. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology,Washington, DC."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201465w"},{"key":"e_1_3_2_29_2","volume-title":"Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. CLSI document M45,3rd ed.Clinical and Laboratory Standards Institute,Wayne, PA.","edition":"3"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.182.10.2928-2936.2000"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)62213-6"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.LAB.0000080599.43791.01"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00288-12"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00099-13"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.06.041"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01103-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01103-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:46:22Z","timestamp":1645476382000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01103-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1128\/AAC.01103-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01103-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"2017-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01103-17"}}